<DOC>
	<DOC>NCT01122953</DOC>
	<brief_summary>To investigate the bioequivalence between two compounds (phenytoin and epamin) by a randomized, single dose study under fasting conditions in healthy volunteers.</brief_summary>
	<brief_title>Bioequivalence Study Of PHENYTOIN Suspension Made By Pfizer, Versus EPAMIN® Made By McNeil LA LLC In Healthy Volunteers Under Fasting Conditions</brief_title>
	<detailed_description>Bioequivalence study in healthy volunteers</detailed_description>
	<mesh_term>Phenytoin</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years Body Mass Index (BMI) of 18 to 26.9 kg/m2 or ± 10% variation of the ideal weight; and a total body weight &gt;50 kg (110 lbs). An informed consent document signed and dated by the subject or a legally acceptable representative. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Any condition possibly affecting drug absorption (eg, gastrectomy). A positive urine drug screen.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>EPAMIN</keyword>
	<keyword>PHENYTOIN</keyword>
</DOC>